Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection
Jesús M. Martín-Campos,
Sheila Ruiz-Nogales,
Daiana Ibarretxe,
Emilio Ortega,
Elisabet Sánchez-Pujol,
Meritxell Royuela-Juncadella,
Àlex Vila,
Carolina Guerrero,
Alberto Zamora,
Cristina Soler i Ferrer,
Juan Antonio Arroyo,
Gemma Carreras,
Susana Martínez-Figueroa,
Rosa Roig,
Núria Plana,
Francisco Blanco-Vaca,
Xarxa d’Unitats de Lípids i Arteriosclerosi (XULA)
Affiliations
Jesús M. Martín-Campos
Metabolic Bases of Cardiovascular Risk Group, Santa Creu i Sant Pau Hospital Research Institute (IR-HSCSP)—Sant Pau Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain
Sheila Ruiz-Nogales
Metabolic Bases of Cardiovascular Risk Group, Santa Creu i Sant Pau Hospital Research Institute (IR-HSCSP)—Sant Pau Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain
Daiana Ibarretxe
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain
Emilio Ortega
Endocrinology and Nutrition Service, Hospital Clínic, 08036 Barcelona, Spain
Elisabet Sánchez-Pujol
Internal Medicine Service, Hospital-Asil de Granollers, Granollers, 08402 Barcelona, Spain
Meritxell Royuela-Juncadella
Internal Medicine Service, Altahia, Xarxa Assistencial Universitària de Manresa, Manresa, 08243 Barcelona, Spain
Àlex Vila
Internal Medicine Service, Hospital de Figueres, Figueres, 17600 Girona, Spain
Carolina Guerrero
Internal Medicine Service, Hospital de Terrassa-Consorci Sanitari de Terrassa, Terrassa, 08227 Barcelona, Spain
Alberto Zamora
Internal Medicine Service, Corporació de Salut del Maresme i La Selva, Hospital de Blanes, Blanes, 17300 Girona, Spain
Cristina Soler i Ferrer
Internal Medicine Service, Hospital Santa Caterina, Salt, 17190 Girona, Spain
Juan Antonio Arroyo
Internal Medicine Service, Santa Creu i Sant Pau Hospital (HSCSP)-IIB Sant Pau, 08041 Barcelona, Spain
Gemma Carreras
Pediatric Service, HSCSP-IIB Sant Pau, 08041 Barcelona, Spain
Susana Martínez-Figueroa
Biochemistry Service, HSCSP-IIB Sant Pau, 08041 Barcelona, Spain
Rosa Roig
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain
Núria Plana
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain
Francisco Blanco-Vaca
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain
Xarxa d’Unitats de Lípids i Arteriosclerosi (XULA)
Familial hypercholesterolemia (FH) is associated with mutations in the low-density lipoprotein (LDL) receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) genes. A pathological variant has not been identified in 30–70% of clinically diagnosed FH patients, and a burden of LDL cholesterol (LDL-c)-raising alleles has been hypothesized as a potential cause of hypercholesterolemia in these patients. Our aim was to study the distribution of weighted LDL-c-raising single-nucleotide polymorphism (SNP) scores (weighted gene scores or wGS) in a population recruited in a clinical setting in Catalonia. The study included 670 consecutive patients with a clinical diagnosis of FH and a prior genetic study involving 250 mutation-positive (FH/M+) and 420 mutation-negative (FH/M−) patients. Three wGSs based on LDL-c-raising variants were calculated to evaluate their distribution among FH patients and compared with 503 European samples from the 1000 Genomes Project. The FH/M− patients had significantly higher wGSs than the FH/M+ and control populations, with sensitivities ranging from 42% to 47%. A wGS based only on the SNPs significantly associated with FH (wGS8) showed a higher area under the receiver operating characteristic curve, and higher diagnostic specificity and sensitivity, with 46.4% of the subjects in the top quartile. wGS8 would allow for the assignment of a genetic cause to 66.4% of the patients if those with polygenic FH are added to the 37.3% of patients with monogenic FH. Our data indicate that a score based on 8 SNPs and the75th percentile cutoff point may identify patients with polygenic FH in Catalonia, although with limited diagnostic sensitivity and specificity.